MedTrace Logo

T-Cell Turnover Following Vaccination With MVA85A

NCT00548444 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2010-01-18

No results posted yet for this study

Summary

This study examines the early immune response to a new vaccine (MVA85A) being developed to combat tuberculosis (TB).

Conditions

Interventions

BIOLOGICAL

MVA85A

Vaccine. Dose: 1 x 10\^8 plaque-forming units (pfu) given by intradermal injection into the deltoid region of the upper arm.

OTHER

Deuterated glucose infusion

6,6D2-glucose given as a timed intravenous infusion. The total dose of deuterated glucose will be 1g/kg volunteer body weight (up to a maximum of 60g).

Sponsors & Collaborators

  • Wellcome Trust

    collaborator OTHER

  • St George's, University of London

    collaborator OTHER

  • University of Oxford

    lead OTHER

Principal Investigators

  • Helen I McShane, MBBS, MRCP, BSc, PhD · University of Oxford

  • Adrian VS Hill, MA, BM BCh, DPhil, DM · University of Oxford

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2010-01-31
Completion
2010-01-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00548444 on ClinicalTrials.gov